Catalyst Pharmaceuticals, Inc. (CPRX)
NASDAQ: CPRX · IEX Real-Time Price · USD
14.89
+0.21 (1.43%)
At close: Apr 26, 2024, 4:00 PM
14.81
-0.08 (-0.54%)
After-hours: Apr 26, 2024, 7:37 PM EDT
Catalyst Pharmaceuticals Revenue
In the year 2023, Catalyst Pharmaceuticals had annual revenue of $398.20M with 85.90% growth. Revenue in the quarter ending December 31, 2023 was $110.57M with 81.98% year-over-year growth.
Revenue (ttm)
$398.20M
Revenue Growth
+85.90%
P/S Ratio
4.41
Revenue / Employee
$2,384,455
Employees
167
Market Cap
1.75B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 398.20M | 184.00M | 85.90% |
Dec 31, 2022 | 214.20M | 73.37M | 52.10% |
Dec 31, 2021 | 140.83M | 21.76M | 18.27% |
Dec 31, 2020 | 119.07M | 16.77M | 16.39% |
Dec 31, 2019 | 102.31M | 101.81M | 20,361.20% |
Dec 31, 2018 | 500.00K | - | - |
Dec 31, 2017 | 0 | - | - |
Dec 31, 2016 | 0 | - | - |
Dec 31, 2015 | 0 | - | - |
Dec 31, 2014 | 0 | - | - |
Dec 31, 2013 | 0 | - | - |
Dec 31, 2012 | 0 | - | - |
Dec 31, 2011 | 0 | - | - |
Dec 31, 2010 | 0 | - | - |
Dec 31, 2009 | 0 | - | - |
Dec 31, 2008 | 0 | - | - |
Dec 31, 2007 | 0 | - | - |
Dec 31, 2006 | 0 | - | - |
Dec 31, 2005 | 0 | - | - |
Dec 31, 2004 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Astrana Health | 1.39B |
NeoGenomics | 591.64M |
Harmony Biosciences Holdings | 582.02M |
Alphatec Holdings | 482.26M |
Beam Therapeutics | 377.71M |
Ginkgo Bioworks Holdings | 251.46M |
Schrödinger | 216.67M |
Recursion Pharmaceuticals | 44.58M |
CPRX News
- 3 days ago - Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full Report Publication in May - GlobeNewsWire
- 6 days ago - Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024 - GlobeNewsWire
- 22 days ago - Jim Cramer recommends five small-cap health-care stocks - CNBC
- 4 weeks ago - Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness Day - GlobeNewsWire
- 4 weeks ago - Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium - GlobeNewsWire
- 6 weeks ago - Santhera's Partner Catalyst Pharmaceuticals Launches AGAMREE® (Vamorolone) in the United States - GlobeNewsWire
- 6 weeks ago - Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD) - GlobeNewsWire
- 7 weeks ago - Catalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare Conference - GlobeNewsWire